Multinational randomized phase 2 trial of consolidation durvalumab with or without novel agents for unresectable non-small cell lung cancer

The PACIFIC trial established durvalumab as the standard-of-care consoliation therapy for unresectable, stage III non-small cell lung cancer without progression after concurrent chemoradiotherapy. Novel immunotherapy combinations involving the anti-CD73 monoclonal antibody oleclumab or the anti-NKG2A monoclonal antibody monalizumab have the potential to build on the durvalumab standard of care. Final analysis of the mulitnational phase 2 COAST trial found that comfirmed objective response rates were numerically higher with durvalumab plus oleclumab or monalizumab than with durvalumab alone (visual abstract). The authors conclude that these results support further evaluation of these combinations in an ongoing, larger, phase 3 trial (PACIFIC-9).